Vasopressin-Receptor Antagonists May Help Treat Wide Range of Conditions
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Vasopressin-Receptor Antagonists May Help Treat Wide Range of Conditions

NEW YORK -- May 9, 2008 -- A study appearing in the May 10, 2008, issue of The Lancet suggests that a new class of drugs called vasopressin-receptor antagonists, or vaptans, may be used to treat a wide range of conditions, including dysmenorrhoea, brain haemorrhage, psychotic disorders, and glaucoma.

In the article, Professor Guy Decaux, Erasmus University Hospital, Brussels, Belgium, and colleagues noted that vaptans can be taken orally or intravenously and work by competing with vasopressin hormone molecules for the same receptor "active sites" on cells, thus blocking the action of vasopressin.

Various subclasses of vaptan have been developed or are in development. Relcovaptan has shown initial positive results in the treatment of dysmenorrhoea, Raynaud's disease, and tocolysis.

A second subclass of vaptans, which target a different cell receptor site, include mozavaptan, lixivaptan, satavaptan, and tolvaptan. These drugs induce diuresis without the loss of mineral salts from the body that accompanies the use of other diuretics. This class of vaptans can be used to treat hyponatraemia. Conivaptan is the only vaptan currently approved by the US Food and Drug Administration for the treatment of hyponatraemia. Drugs in this class are in development to treat a number of conditions, including renal failure related to polycystic kidney disease, diabetic nephropathy, cirrhosis, and depression.

There also have been promising preliminary studies of vaptans for the treatment of glaucoma, Meniere's disease, brain haemorrhage, and small-cell cancer.

SOURCE: The Lancet

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities